The emerging role of fusion inhibitors in HIV infection.

被引：14

作者：

De Clercq E. ^{[1
]}

机构：

[1] Rega Institute for Medical Research, Katholieke Universiteit Leuven

来源：

Drugs in R & D | 1999年 / 2卷 / 5期

关键词：

Human Immunodeficiency Virus; Adis International Limited; Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus Replication; CXCR4 Antagonist;

D O I：

10.2165/00126839-199902050-00010

中图分类号：

学科分类号：

摘要：

Fusion of HIV with its host cell requires the interaction of the viral envelope glycoprotein 120 (gp120) with the chemokine receptor CXCR4 [T cell-tropic (T-tropic) or X4 HIV strains] or CCR5 [macrophage-tropic (M-tropic) or R5 HIV strains] followed by a 'spring-loaded' action of the glycoprotein 41 (gp41) that ensures fusion of the viral and cellular lipid membranes and permits the viral nucleocapsid to enter the cell. The overall fusion process can be blocked by a number of compounds. These include siamycin analogues, SPC 3 (a synthetic peptide derived from the V3 domain of gp120), pentafuside (T 20, DP 178) [a synthetic peptide corresponding to amino acid residues 127 to 162 of gp41], the betulinic acid derivative RPR 103611, TAK 779 (a low molecular weight non-peptide CCR5 antagonist) and a number of compounds (T 22, T 134, ALX40-4C, CGP64222 and AMD 3100) that are targeted at the CXCR4 receptor. In particular, the bicyclam AMD 3100 has proved highly potent and selective as a CXCR4 antagonist that blocks the infectivity of X4 HIV strains in the nanomolar concentration range. The proof-of-concept that fusion inhibitors should be able to suppress viral replication in vivo has been demonstrated with pentafuside. Pentafuside and AMD 3100 have now proceeded to phase II clinical trials.

引用

页码：321 / 331

页数：10

共 127 条

[31] Bechtold CM(1997)Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions Proc Natl Acad Sci U S A 94 3548-53
[32] Yahi N(1992)A smallmolecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor Proc Natl Acad Sci U S A 89 5286-90
[33] Fantini J(1994)An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication Antimicrob Agents Chemother 38 668-74
[34] Baghdiguian S(1996)Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event Antiviral Res 29 209-19
[35] Delézay O(1996)Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 Antiviral Res 29 297-307
[36] Hammache D(1996)The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding J Virol 70 689-96
[37] Fantini J(1997)Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1 Antimicrob Agents Chemother 41 2616-20
[38] Barbouche R(1997)The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication J Exp Med 186 1383-8
[39] Fenouillet E(1997)Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120 Antiviral Res 35 147-56
[40] Papandréou M-J(1998)Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 Nat Med 4 72-7

← 1 2 3 4 5 6 7 8 9 10 →